论文部分内容阅读
1992年,中国预防医学科学院病毒研究所的一项基因工程的干扰素项目引起了科招的兴趣。用科招的话说,这是科招投资的正业,因为这是一个“863”计划的科研成果,它的高科技水平的前景不可限量。为此,科招与中国医学科学院合作成立了一家创业企业——三元基因。科招为三元基因倾注了大量的心血,以致于三元基因总经理程永庆说,没有科招,也就没有三元基因。在科招投资三元基因的过程中,三元基因历经了6届董事会的变更,投资的不易可见一斑。而三元基因则显得异常争气,在生物制药领域发展得是虎虎生气,如今,科招与三元基因一起为今年在香港创业板上市而努力着。那么,成功的背后是什么?
In 1992, a genetically engineered interferon project at the Institute of Virology of the Chinese Academy of Preventive Medicine caught the interest of the department. In the words of the Branch, this is the real cause of investment in the Branch because it is a scientific achievement of the “863” project, and its high-tech prospect has an indefinite future. To this end, the Branch strokes and the Chinese Academy of Medical Sciences set up a venture - ternary gene. Branch trillion yuan gene poured a lot of painstaking care, so that general manager of the yuan gene Cheng Yongqing said that there is no section strokes, there is no ternary gene. In the process of investment and development of ternary gene, the ternary gene has gone through changes of the 6th session of the board of directors, and the investment is not easy to see. The ternary gene is unusually competitive, developed in the field of biopharmaceutical tiger angry, and now, the Department of trichomoniasis gene together with this year’s listing in Hong Kong and work hard. So what is behind the success?